Release Date: 21/11/19 14:30 Summary: Proposed asset sales to reinforce portfolio net asset value Price Sensitive: Yes Download Document 308.95KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%